Anticipated shortage
Anticipated shortage as Pfizer transitions manufacturing post-patent expiry. Rheumatoid arthritis patients should not stop JAK inhibitor therapy without guidance.
Expected resolution: 30 November 2025
Alternatives:
- Olumiant (baricitinib) 4 mg — alternative JAK inhibitor
- Rinvoq (upadacitinib) — newer JAK inhibitor (check PBS eligibility)
tofacitinib citrate
Xeljanz
5 mg · tablet · JAK Inhibitors
PBS Pricing
| General patient co-payment | $31.60 |
| Concession co-payment | $7.70 |
| Full dispensed price | $1,124.80 |
PBS Information
- Item code
- IMM015
- Drug name
- tofacitinib citrate
- Brand name
- Xeljanz
- Manufacturer
- Pfizer
- Formulation
- tablet
- Strength
- 5 mg
- Max quantity
- 60 units
- Max repeats
- 5
- PBS listed
- Yes
- Therapeutic group
- JAK Inhibitors
TGA Reference: TGA-MSI-2025-035 · Sponsor: Pfizer Australia Pty Ltd
MedWatch is for informational purposes only and does not constitute medical advice. Never stop or change your medicines without consulting your doctor or pharmacist. In an emergency, call 000. Medication queries: National Medicines Line 1300 633 424.